Orris

Make a research proposal on the topic regarding Title: Drug Compliance, Immunological Status, and Psychosocial Challenges Among HIV-Positive Patients Below 21 Years in Zambia Despite the child friendly support program, and interventions

I'll gather evidence from multiple sources in parallel to build a well-grounded proposal.
Reading File
Searching PubMed

antiretroviral adherence adolescents HIV sub-Saharan Africa

Searching the Web

Zambia child-friendly HIV support program adolescents ART adherence psychosocial 2023 2024

Now let me get deeper details from key PubMed articles and the medical library simultaneously.
Reading Article

PMID: 37200399

Reading Article

PMID: 35983685

Reading Article

PMID: 40473447

Finding Sources
Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC13123187

Reading Article

PMID: 37956242

Reading Article

PMID: 35951621

Finding Sources
Searching PubMed

HIV Zambia children adolescents immunological CD4 viral suppression

Finding Sources
Searching PubMed

mental health depression HIV positive youth Africa

Searching the Web

Zambia HIV statistics children adolescents under 21 2024 UNAIDS PEPFAR

I now have sufficient evidence to write a comprehensive, well-cited research proposal. Let me compile it.Here is the full research proposal, grounded in the evidence gathered:

RESEARCH PROPOSAL

TITLE

Drug Compliance, Immunological Status, and Psychosocial Challenges Among HIV-Positive Patients Below 21 Years in Zambia: A Persistent Gap Despite Child-Friendly Support Programs and Interventions

COVER PAGE

Principal Investigator[Name, Credentials, Institution]
Co-Investigators[Names, Institutions]
Submitting Institution[University/Research Institute, Zambia]
Date of SubmissionJune 2026
Proposed Duration24 months
Target Study SitesSelected public health facilities, Lusaka and Copperbelt Provinces, Zambia

ABSTRACT

Background: Zambia carries one of the highest HIV burdens in sub-Saharan Africa (SSA), with an estimated HIV prevalence of 8.7% among adults aged 15-49 years per the 2024 Zambia Demographic and Health Survey (ZDHS), and an HIV prevalence of 1.2% among children aged 2-14 years. Despite the national scale-up of child-friendly and adolescent-friendly HIV services, young people under 21 years living with HIV continue to experience disproportionately poor treatment outcomes relative to adults. Antiretroviral therapy (ART) adherence rates among adolescents in SSA are estimated at only 65%, with viral load suppression as low as 55%, and loss to follow-up (LTFU) at 15%. The psychosocial dimensions - including stigma, disclosure challenges, mental health comorbidities, and socioeconomic barriers - remain inadequately addressed by existing programs.
Objectives: This study aims to (1) determine the level of drug compliance (ART adherence) among HIV-positive patients below 21 years in selected Zambian health facilities; (2) assess their immunological status through CD4 cell counts and viral load measurements; (3) identify and characterize the psychosocial challenges they face; and (4) examine the extent to which current child-friendly support programs address these challenges.
Methods: A mixed-methods cross-sectional design will be used. Quantitative data on adherence and immunological parameters will be collected from 300 participants (aged 0-20 years) across six facilities in Lusaka and the Copperbelt. Qualitative in-depth interviews and focus group discussions will explore psychosocial experiences. Clinical records will supplement primary data collection.
Expected Outcomes: Findings will generate actionable evidence to strengthen Zambia's adolescent HIV response, inform policy revision around child-friendly program design, and contribute to the global literature on youth HIV care in high-burden settings.
Keywords: HIV, antiretroviral therapy, drug compliance, adherence, immunological status, psychosocial, adolescents, children, Zambia, child-friendly services

1. INTRODUCTION AND BACKGROUND

1.1 Global and Regional HIV Burden Among Young People

HIV/AIDS remains one of the most significant public health challenges of our time. Globally, an estimated 120,000 children acquired HIV in 2024, and 75,000 children died from HIV-related causes in that same year (WHO, 2024). In sub-Saharan Africa, adolescents and young people bear the heaviest burden: in 2023, 77% of new HIV infections among adolescent girls and young women aged 15-24 years occurred in SSA, with 60% concentrated in eastern and southern Africa (UNAIDS, 2024). Zambia sits at the center of this epidemic.
According to the 2024 Zambia Demographic and Health Survey, HIV prevalence among adults aged 15-49 years stands at 8.7%, down from 11.1% in 2018 - a meaningful decline. However, children are being left behind: an estimated 3,000 children aged 0-2 years were newly infected through mother-to-child transmission in 2025, with a transmission rate of 6%, still above the global target of below 5%. Thirty-eight percent of new infections in Zambia occur among young people aged 15-24 years (UNAIDS, 2025). Despite national progress, HIV incidence remains high among youth, and the consequences of poor treatment uptake and adherence in this age group are severe.

1.2 The Problem of Drug Compliance in Young People Living with HIV

Achieving viral suppression requires near-perfect adherence to ART - historically defined as taking at least 95% of prescribed doses. This target is extremely difficult to sustain among children and adolescents. A 2023 mixed-methods systematic review and meta-analysis of 66 studies involving 53,217 adolescents (aged 10-19 years) across SSA found an ART adherence rate of only 65% (95% CI: 56-74), viral load suppression of 55% (95% CI: 46-64), and unsuppressed viral load of 41% (95% CI: 32-50) (Hlophe et al., 2023, PMID: 37200399). A more recent 2025 Lancet HIV systematic review and meta-analysis of 52 studies involving 169,949 children and adolescents on ART in SSA reported an overall prevalence of unsuppressed viral load of 26.47% (95% CI: 23.06-29.87) (Mukuku et al., 2025, PMID: 40473447). These figures indicate that despite widespread ART availability, a substantial proportion of young patients are not achieving the treatment outcomes needed to protect their health and prevent onward transmission.
Furthermore, loss to follow-up (LTFU) is a critical indicator of program failure. A 2022 systematic review and meta-analysis found that approximately 15% of adolescents living with HIV in SSA were lost to follow-up from ART programs, with older adolescents (15-19 years) 43% more likely to be lost than younger adolescents (10-14 years) (Leshargie et al., 2022, PMID: 35951621). This age-related differential has direct implications for program design in Zambia, where the transition between pediatric and adolescent care remains a vulnerable period.

1.3 Immunological Consequences of Non-Adherence

Suboptimal ART adherence directly translates into immunological deterioration. CD4 T-lymphocyte depletion, the hallmark of HIV disease progression, accelerates when viral replication is not adequately suppressed. In children, immunological thresholds for disease staging and treatment eligibility differ from adults, reflecting distinct immune system maturation. The 2025 meta-analysis by Mukuku et al. identified key factors associated with unsuppressed viral load in children and adolescents, including younger age (under 5 years), advanced WHO clinical staging, low CD4 counts, history of opportunistic infections, nevirapine-based regimens, drug substitution history, and non-disclosure of HIV status. These findings confirm that immunological outcomes are not independent of psychosocial and behavioral factors - they are deeply intertwined.

1.4 Psychosocial Challenges Faced by Young People Living with HIV

Psychosocial challenges represent a primary driver of poor adherence and disengagement from care in young people. A 2022 systematic review (Chem et al., PMID: 35983685) synthesizing evidence from 32 studies across 11 countries - with Zambia producing the most included studies (7) - identified seven categories of health-related needs among adolescents living with HIV on ART in SSA. In descending order of occurrence, these were: (1) psychosocial needs (stigma reduction, disclosure and privacy support, difficulty accepting diagnosis); (2) dependency of care (need for family and provider support, desire for autonomy); (3) self-management needs (medication adherence support, reduced ART side effects); (4) non-responsive health services; (5) need for food, financial, and material support; (6) inadequate information about HIV; and (7) developmental and growth needs.
A recent qualitative study conducted in Lusaka, Zambia (PMC13123187) found that adolescents living with HIV experienced multilevel barriers to adherence spanning intrapersonal, interpersonal, institutional, community, and structural-policy dimensions. Specific barriers included stigma, emotional distress, difficulties taking medication in school settings (due to rigid schedules, limited privacy, and fear of inadvertent disclosure), inconsistent caregiving, transport costs, and drug access challenges. Adolescents adapted through spirituality, routine-building, and peer relationships, but these coping mechanisms were fragile without structural support.
Kaplan & Sadock's Comprehensive Textbook of Psychiatry notes that a significant number of HIV-infected children and adolescents have pre-existing psychiatric illness requiring specialist management. Among adolescents on ART, "lack of almost perfect adherence to daily regimes continues" to be a challenge, and untreated depression contributes to sexual risk behaviors and poorer adherence, further increasing morbidity and HIV transmission risk. Psychiatric comorbidities - including depression, anxiety, post-traumatic stress disorder, and behavioral disorders - are elevated in this population and often go undetected and untreated in resource-limited settings.

1.5 Child-Friendly Support Programs and Their Limitations

Zambia has made significant strides in implementing adolescent- and child-friendly HIV services. The 2020 Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection prescribe specialized protocols for pediatric ART initiation, adherence counseling, and referral to youth-friendly services. PEPFAR and Global Fund support have underwritten substantial program expansion. However, these programs have consistently underperformed against expectations:
  • Adherence interventions exist, but the 2023 systematic review by Hlophe et al. identified 13 support-focused interventions for improved ART adherence, yet the pooled adherence rate of 65% demonstrates that existing programs are insufficient.
  • A 2023 systematic review of peer support interventions for adolescents living with HIV in SSA found mixed and mostly non-significant results for retention, adherence, and mental health outcomes, with most studies deemed only moderate in methodological quality (Ahmed et al., 2023, PMID: 37956242).
  • The qualitative Lusaka study found that child-friendly services at health facilities did not extend to non-health institutional settings such as schools, leaving adolescents to navigate adherence alone in environments not designed to support them.
  • Financial crises threaten program continuity. The 2025 UNAIDS report highlighted a US$367 million reduction in PEPFAR's Zambia budget and a US$21 million cut under Global Fund grant reprioritization, with an estimated US$500 million annual funding need.
These gaps define the rationale for this study.

2. PROBLEM STATEMENT

Despite over a decade of child-friendly and adolescent-friendly HIV program implementation in Zambia, young people below 21 years living with HIV continue to experience unacceptably low ART adherence, high rates of viral non-suppression, progressive immunological decline, and pervasive psychosocial distress. Existing interventions have not closed this gap. There is a critical need for a comprehensive, context-specific investigation into the nature, magnitude, and determinants of drug non-compliance, immunological deterioration, and psychosocial challenges in this population, particularly in Zambia's unique socioeconomic and cultural context, and within the specific framework of existing child-friendly support programs.

3. RESEARCH QUESTIONS

  1. What is the level of drug compliance (ART adherence) among HIV-positive patients below 21 years accessing care at selected health facilities in Zambia?
  2. What is the current immunological status (CD4 count, viral load, WHO clinical stage) of these patients, and how does it correlate with adherence patterns?
  3. What specific psychosocial challenges do HIV-positive patients below 21 years face, and how do these challenges influence drug compliance and immunological outcomes?
  4. To what extent do current child-friendly support programs and interventions address the drug compliance, immunological, and psychosocial needs of this population?
  5. What factors (individual, family, health system, and community level) moderate the relationship between psychosocial challenges, drug compliance, and immunological status in this group?

4. OBJECTIVES

4.1 Primary Objectives

  1. To determine the prevalence and level of ART drug compliance among HIV-positive patients below 21 years in selected Zambian health facilities.
  2. To assess the immunological status (CD4 cell count, viral load suppression rate, WHO clinical stage) of HIV-positive patients below 21 years.
  3. To identify and characterize the psychosocial challenges faced by HIV-positive patients below 21 years in Zambia.

4.2 Secondary Objectives

  1. To examine the association between drug compliance, immunological status, and psychosocial challenges in this population.
  2. To evaluate the perceived effectiveness and coverage of existing child-friendly support programs and interventions from the perspectives of patients, caregivers, and healthcare workers.
  3. To identify modifiable individual, family, and system-level determinants of poor drug compliance in this age group.
  4. To generate evidence-based recommendations for the strengthening of child-friendly HIV support programs in Zambia.

5. HYPOTHESES

H1: ART drug compliance among HIV-positive patients below 21 years in Zambia is significantly lower than the WHO recommended 95% threshold.
H2: There is a statistically significant positive association between ART drug compliance and immunological status (viral load suppression and CD4 count) in this population.
H3: Psychosocial challenges (stigma, disclosure difficulties, mental health comorbidities, socioeconomic barriers) are significantly associated with poor drug compliance and worse immunological outcomes among HIV-positive patients below 21 years.
H4: Current child-friendly support programs incompletely address the psychosocial, structural, and adherence-related needs of HIV-positive patients below 21 years in Zambia.

6. SIGNIFICANCE OF THE STUDY

This study is significant on multiple levels:
Clinical significance: Findings will directly inform clinical practice by identifying subgroups at highest risk of non-adherence and immunological deterioration, enabling targeted intensification of support.
Program significance: The evaluation of child-friendly program effectiveness will provide actionable data to the Ministry of Health, PEPFAR, and the Global Fund as Zambia redesigns its HIV program architecture in the context of funding constraints.
Policy significance: Evidence generated will feed into policy revision around pediatric and adolescent ART program standards, including school-based support integration, mental health service integration, and caregiver support.
Academic significance: This study will contribute to the global literature on adolescent HIV care in high-burden settings, with 7 prior studies from Zambia already serving as the backbone of regional systematic reviews. Adding contemporary, comprehensive Zambian data - covering the full under-21 age spectrum - fills a critical evidence gap.
National significance: Zambia's 2025 UNAIDS report specifically identified children as being "left behind" in the national HIV response. This study directly addresses that national priority.

7. LITERATURE REVIEW

7.1 HIV Epidemiology in Children and Adolescents in Zambia

Zambia has made substantial progress in reducing overall HIV burden, cutting new infections from 63,000 in 2010 to 30,000 in 2025, and reducing AIDS-related deaths by 73%. However, the 2024 ZDHS documented an HIV prevalence of 1.2% among children aged 2-14 years, confirming that pediatric HIV remains a persistent public health challenge. Mother-to-child transmission rates have declined from approximately 30% in 2005 to 5.9% by 2025, but remain above the global elimination target of below 5%.

7.2 ART Adherence in Young People

ART adherence in children and adolescents differs substantially from that in adults due to developmental, cognitive, and social factors. The NIH Pediatric ARV Guidelines note that adherence may be jeopardized by social and health issues including substance use, poor mental health, death of family members, unstable housing, poverty, violence, and limited social support. Children with perinatally-acquired HIV and adolescents with behaviorally-acquired HIV enter care at different developmental stages with different caregiver dynamics, complicating adherence support. The adolescent transition from pediatric to adult care represents a particularly vulnerable period.
The 2023 meta-analysis by Hlophe et al. synthesized six thematic barriers to ART in SSA: social barriers (stigma, lack of family support), patient-based barriers (forgetting, pill fatigue, side effects), economic barriers (transport, food insecurity), health system barriers (long queues, stock-outs, unfriendly staff), therapy-based barriers (regimen complexity, side effects), and cultural barriers (traditional medicine use, belief systems). Three facilitators were identified: social support, counseling, and education and confidentiality guarantees.

7.3 Immunological Outcomes

The 2025 Lancet HIV meta-analysis (Mukuku et al.) provides the most current estimates of unsuppressed viral load in children and adolescents on ART in SSA: 26.47% overall, 26.01% specifically in children under 15, and 24.76% in adolescents aged 10-19. Factors driving unsuppressed viral load include orphan status, rural residence, non-disclosure, poor adherence, advanced clinical staging, low CD4 counts, nevirapine-based regimens, and lack of co-trimoxazole prophylaxis. Immunological and behavioral factors are deeply interlinked, supporting a biopsychosocial research framework.

7.4 Psychosocial Challenges

The psychosocial needs of adolescents living with HIV have been extensively documented. Stigma - both internalized and community-based - is consistently identified as the most prevalent barrier to adherence and care engagement. Disclosure challenges (when to disclose, to whom, and fear of consequences) create sustained psychological burden. A 2025 study from Uganda found that HIV status disclosure challenges were directly associated with mental health challenges in children and adolescents (Kirabira et al., PMID: 41068217). A 2025 review of mental health interventions for young people living with HIV/AIDS in SSA highlighted the high prevalence of depression, anxiety, and post-traumatic stress, and the inadequacy of mental health service integration into HIV programs (Adjorlolo et al., PMID: 40342493).
The Lusaka qualitative study (2025) specifically found that within school environments, rigid schedules, limited privacy, and fear of disclosure made routine ART-taking extremely difficult. Boarding school arrangements, permission requirements for clinic visits, and competing academic demands further disrupted adherence routines.

7.5 Child-Friendly Programs and Their Effectiveness

Zambia's child-friendly HIV program framework includes adolescent-friendly health services (AFHS), peer support groups, differentiated service delivery (DSD) models (community ART groups, adherence clubs, appointment spacing), adherence counseling, and psychosocial support. The WHO African Regional Office strongly recommends adolescent-friendly health services as standard of care for this population.
Despite these investments, the evidence of effectiveness is mixed. The 2023 systematic review of peer support interventions (Ahmed et al.) found that group-based peer support - the most common modality - was generally not associated with significant improvements in retention, adherence, or mental health outcomes in rigorous studies. The Chem et al. review highlighted an ecological mismatch: adolescents, caregivers, and healthcare providers each prioritize different needs, with psychosocial support ranked highest by adolescents but financial support and system responsiveness ranked highest by caregivers and providers respectively.

8. CONCEPTUAL FRAMEWORK

This study is guided by the Social-Ecological Model (SEM) and the World Health Organization's Multi-Level Framework for Adolescent Health. Within the SEM, drug compliance, immunological status, and psychosocial outcomes are understood as products of interacting influences across five levels:
  1. Intrapersonal level: Age, sex, developmental stage, HIV knowledge, mental health status, pill fatigue, self-efficacy, disclosure status
  2. Interpersonal level: Family structure, caregiver support, peer relationships, disclosure dynamics, stigma experiences
  3. Organizational/Institutional level: Health facility quality, child-friendly service availability, school environment, clinic scheduling
  4. Community level: Socioeconomic factors, transport access, cultural norms around HIV, community stigma
  5. Policy/Structural level: National HIV guidelines, funding levels, PEPFAR/Global Fund support, drug supply chain reliability
The framework posits that psychosocial challenges at multiple levels interact bidirectionally with drug compliance behaviors, and together determine immunological outcomes. Child-friendly support programs intervene primarily at the organizational and interpersonal levels, but the persistence of poor outcomes suggests insufficient attention to intrapersonal mental health, community-level stigma, and structural-level barriers.

9. METHODOLOGY

9.1 Study Design

A concurrent mixed-methods cross-sectional study will be employed. Quantitative methods will assess the prevalence and correlates of ART adherence and immunological status. Qualitative methods (in-depth interviews and focus group discussions) will explore lived psychosocial experiences and perceptions of child-friendly program effectiveness.

9.2 Study Setting

The study will be conducted at six health facilities in two provinces: Lusaka Province (urban, peri-urban) and Copperbelt Province (urban, mining communities). Facilities will include four primary health centers and two first-level (district) hospitals with established pediatric and adolescent HIV clinics. These provinces carry a high HIV burden and have established adolescent-friendly HIV services, making them suitable for evaluating both the challenges and the program response.

9.3 Study Population

Inclusion Criteria:
  • HIV-positive patients aged 0-20 years (below 21 years)
  • Enrolled in ART at a selected study facility for at least 6 months
  • Aware of their HIV-positive status (or in the case of young children, primary caregiver is aware)
  • Able to participate in data collection (or caregiver able to participate on behalf of young children under 10 years)
  • Voluntary informed consent/assent provided
Exclusion Criteria:
  • Newly initiated on ART (less than 6 months)
  • Severe cognitive impairment precluding meaningful participation
  • Acutely ill requiring immediate hospitalization

9.4 Sample Size

Using Cochran's formula for prevalence studies, with an estimated ART adherence prevalence of 65% (from Hlophe et al., 2023), 95% confidence level, and 5% margin of error:
n = Z²P(1-P)/e² = (1.96)²(0.65)(0.35)/(0.05)² ≈ 350
Adjusting for a 15% non-response and LTFU rate: N ≈ 400 participants (approximately 67 per facility across six sites).
For the qualitative component, 35 in-depth interviews (20 ALHIV aged 10-20 years, 15 caregivers) and 6 focus group discussions (one per facility, 6-10 participants each) will be conducted, guided by thematic saturation.

9.5 Sampling Strategy

  • Quantitative: Consecutive sampling of eligible patients attending routine clinic appointments until the required sample size is reached at each facility.
  • Qualitative: Purposive sampling to ensure diversity in age, sex, adherence profile (high vs. low), and caregiver type.

9.6 Data Collection

9.6.1 Quantitative Data

A structured, pre-tested interviewer-administered questionnaire will collect:
Section A - Sociodemographic Data: Age, sex, grade/schooling status, caregiver type, household size, socioeconomic indicators (income, food security), province, facility type.
Section B - Drug Compliance/ART Adherence:
  • Self-reported adherence using the Visual Analogue Scale (VAS) - validated for use in SSA
  • 30-day recall adherence (number of missed doses in last 30 days)
  • MEMS (Medication Event Monitoring System) cap data where available
  • Pill count (where applicable)
  • Caregivers/patients will also be asked about barriers to adherence using a validated barriers checklist adapted from the Hlophe et al. framework (2023)
Section C - Immunological Status: Extracted from clinical records:
  • Most recent CD4 cell count (cells/mm³)
  • Most recent viral load (copies/mL) - classified as suppressed (<1000 copies/mL) or unsuppressed
  • WHO clinical staging
  • Current ART regimen
  • Duration on current regimen
  • History of regimen substitution
Section D - Psychosocial Assessment:
  • HIV stigma: Berger HIV Stigma Scale (adapted, 40-item)
  • Depression screening: Patient Health Questionnaire (PHQ-9) for adolescents ≥12 years; Children's Depression Inventory (CDI) for ages 7-11
  • Anxiety: Generalized Anxiety Disorder Scale (GAD-7) for adolescents ≥12 years
  • Social support: Medical Outcomes Study Social Support Survey (MOS-SSS)
  • Disclosure status and history
  • Self-esteem: Rosenberg Self-Esteem Scale (RSES)
Section E - Program Utilization: Enrollment in adolescent-friendly services, peer support groups, adherence clubs, DSD models, frequency of psychosocial support sessions received.

9.6.2 Qualitative Data

In-depth interview topic guides for ALHIV will explore:
  • Daily experiences of taking ART
  • Stigma and disclosure experiences
  • Emotional and psychological impact of HIV diagnosis
  • School environment and adherence challenges
  • Family/caregiver dynamics
  • Perceptions of health facility services (adolescent-friendliness, privacy, respect)
  • Perceived gaps in current programs
Focus group discussions with caregivers will explore similar themes from the caregiver perspective.
A separate key informant interview guide will be used for healthcare workers (nurses, counselors, clinical officers) to assess their perspectives on program implementation, barriers, and recommendations.

9.6.3 Clinical Record Review

Standardized data extraction forms will be used to abstract relevant clinical data from patient health records, including ART regimen history, immunological monitoring results, and program engagement history.

9.7 Data Management and Analysis

Quantitative Analysis:
  • Data will be entered into REDCap and analyzed using SPSS version 26 and STATA version 16
  • Descriptive statistics (frequencies, means, standard deviations, proportions) for all key variables
  • Bivariate analysis: Chi-square tests (categorical variables), t-tests/Mann-Whitney U (continuous variables) to identify associations between adherence, immunological outcomes, and psychosocial variables
  • Multivariable logistic regression to identify independent predictors of poor ART adherence (outcome: VAS <95% or VL ≥1000 copies/mL)
  • Pearson/Spearman correlation to assess the relationship between adherence scores and CD4 counts/viral load
  • Significance threshold: p <0.05
Qualitative Analysis:
  • All interviews and FGDs will be audio-recorded (with consent), transcribed verbatim, and translated where necessary
  • Analysis using ATLAS.ti software, applying a hybrid inductive-deductive thematic analysis approach
  • Initial open coding, followed by axial coding and theme development guided by the SEM framework
  • Member checking and peer debriefing for rigor
Mixed-Methods Integration:
  • Joint display analysis (side-by-side comparison of quantitative trends and qualitative themes)
  • Triangulation of findings to produce converged, divergent, or elaborative conclusions

9.8 Quality Control

  • All research assistants will undergo three days of standardized training in data collection protocols, interviewing techniques, and child-protection procedures
  • Pre-testing of all instruments at a non-study facility
  • Double-entry verification for 20% of quantitative data
  • Weekly supervision and data quality checks
  • Clinical record data will be cross-verified against patient-reported adherence to assess concordance

10. ETHICAL CONSIDERATIONS

Ethical approval will be sought from the University of Zambia Biomedical Research Ethics Committee (UNZA BREC) and from each study facility's institutional review board. The following ethical principles will be upheld:
Informed Consent and Assent:
  • Written informed consent from participants aged 18-20 years and from parents/guardians of participants below 18 years
  • Written or verbal assent from participants aged 7-17 years in an age-appropriate format
  • Consent for audio recording will be obtained separately
  • Right to withdraw at any time without penalty to care
Confidentiality and Privacy:
  • All data will be de-identified; participants assigned unique study codes
  • Data stored on password-protected, encrypted servers
  • Interview rooms will ensure complete privacy
  • Strict protocols to prevent inadvertent disclosure of HIV status
Child Protection:
  • The study will adhere to Zambia's Children's Code Act (2022) and relevant UNICEF child protection standards
  • Research assistants trained in safeguarding procedures
  • Referral pathways established for participants identified with acute mental health needs, suicidal ideation, or abuse
Benefit-Risk Balance:
  • The study poses minimal physical risk; some risk of emotional distress during interviews
  • All participants will be offered referral to counseling services
  • No experimental interventions; data collection only
  • Potential benefits: individually tailored referrals, contribution to improved services
Community Engagement:
  • Health facility management and patient advisory groups will be engaged prior to data collection
  • Findings will be disseminated back to facility staff and community stakeholders

11. LIMITATIONS

  1. Cross-sectional design precludes causal inference between psychosocial factors, adherence, and immunological outcomes.
  2. Self-reported adherence is subject to social desirability bias. Viral load data will serve as an objective cross-check.
  3. Clinical record incompleteness at some facilities may limit extraction of immunological data.
  4. Selection bias as consecutive sampling may over-represent engaged patients; those most disengaged (LTFU) will not be captured.
  5. Generalizability is limited to urban and peri-urban facilities; rural settings may present different dynamics.
  6. Language barriers will be mitigated through use of trained interpreters and translated instruments (English/Nyanja/Bemba), but some nuance may be lost.

12. DISSEMINATION PLAN

Findings will be disseminated through:
  • Peer-reviewed publications in international journals (e.g., Journal of the International AIDS Society, PLoS ONE, Lancet HIV)
  • Presentations at national conferences (Zambia National HIV Research Symposium) and international conferences (IAS Conference on HIV Science)
  • Policy briefs submitted to the Zambia Ministry of Health, National AIDS Council, PEPFAR Zambia, and UNAIDS
  • Community feedback meetings at study health facilities
  • Open-access data deposition to promote further research

13. WORK PLAN AND TIMELINE

PhaseActivityMonths
Phase 1: PreparationProtocol finalization, ethics submission, tool development, trainingMonths 1-3
Phase 2: Pre-testingInstrument pre-testing, refinement, REDCap setupMonth 4
Phase 3: Data CollectionQuantitative surveys, clinical record extraction, qualitative IDIs and FGDsMonths 5-14
Phase 4: AnalysisQuantitative and qualitative analysis, mixed-methods integrationMonths 15-19
Phase 5: DisseminationReport writing, manuscript preparation, policy briefs, stakeholder feedbackMonths 20-24

14. BUDGET OVERVIEW

CategoryEstimated Cost (USD)
Personnel (PI, Co-Is, Research Assistants x6, Data Manager, Qualitative Analyst)$45,000
Field data collection (transport, per diem, printing)$12,000
Participant reimbursements (transport support)$8,000
Laboratory (viral load/CD4 verification where needed)$10,000
Data management software (REDCap, SPSS, ATLAS.ti)$3,500
Training and workshops$4,000
Dissemination (conferences, open-access publication fees)$6,000
Indirect/overhead costs (15%)$13,275
Total Estimated Budget$101,775
Detailed budget justification available on request.

15. RESEARCH TEAM AND CAPACITY

The proposed research team brings together expertise in infectious disease/HIV medicine, public health, child and adolescent psychiatry, qualitative social science methods, and biostatistics. The team has prior experience conducting research in Zambian health facilities and established relationships with the Ministry of Health and implementing partners. Details of qualifications and roles will be appended in CVs.

16. REFERENCES

  1. Hlophe LD, Tamuzi JL, Shumba CS, Nyasulu PS. Barriers and facilitators to anti-retroviral therapy adherence among adolescents aged 10 to 19 years living with HIV in sub-Saharan Africa: A mixed-methods systematic review and meta-analysis. PLoS One. 2023;18(5):e0276411. PMID: 37200399
  2. Mukuku O, Govender K, Wembonyama SO, Kiakuvue YN. Magnitude and characteristics of unsuppressed HIV viral load in children and adolescents on antiretroviral therapy in sub-Saharan Africa: a systematic review and meta-analysis. Lancet HIV. 2025. PMID: 40473447
  3. Chem ED, Ferry A, Seeley J, et al. Health-related needs reported by adolescents living with HIV and receiving antiretroviral therapy in sub-Saharan Africa: a systematic literature review. J Int AIDS Soc. 2022;25(8):e25921. PMID: 35983685
  4. Leshargie CT, Demant D, Burrowes S, Frawley J. The proportion of loss to follow-up from antiretroviral therapy (ART) and its association with age among adolescents living with HIV in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One. 2022;17(8):e0272906. PMID: 35951621
  5. Ahmed CV, Doyle R, Gallagher D, et al. A Systematic Review of Peer Support Interventions for Adolescents Living with HIV in Sub-Saharan Africa. AIDS Patient Care STDS. 2023;37(11):519-530. PMID: 37956242
  6. Mengesha MM, Teshome A, Ajema D, et al. The association between HIV diagnosis disclosure and adherence to anti-retroviral therapy among adolescents living with HIV in Sub-Saharan Africa: A systematic review and meta-analysis. PLoS One. 2023. PMID: 37167342
  7. Adjorlolo S, Boakye DS, Xatse E. Mental Health Interventions for Young People Living With HIV/AIDS in Sub-Saharan Africa: A Systematic Review. AIDS Res Treat. 2025. PMID: 40342493
  8. Kirabira J, Rukundo GZ, Atim L, et al. Mental health challenges and HIV status disclosure among children and adolescents living with HIV in Eastern Uganda. Sci Rep. 2025. PMID: 41068217
  9. HIV Care Through Their Eyes: Navigating HIV Services and ART Adherence Among Adolescents and Their Caregivers in Lusaka, Zambia. PMC13123187. 2025.
  10. UNAIDS. Global AIDS Update 2025: AIDS: Crisis and the Power to Transform. Geneva: UNAIDS; 2025.
  11. UNAIDS. HIV and Adolescent Girls and Young Women - Thematic Briefing Note. 2024.
  12. World Health Organization. HIV Data and Statistics. Global HIV Programme; 2024.
  13. Zambia Ministry of Health. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection 2020. Lusaka: Ministry of Health; 2020.
  14. Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 10th ed. Philadelphia: Wolters Kluwer; 2017. [Medical Library]
  15. NIH Pediatric ARV Guidelines. Adherence to Antiretroviral Therapy in Children and Adolescents Living with HIV. clinicalinfo.hiv.gov; 2024.
  16. WHO Regional Office for Africa. HIV/AIDS: Adolescent-Friendly Health Services. AFRO; 2024.
End of Proposal
---You've run out of free credits. Sign up for a free account to continue using Orris.
This is a shared conversation. Sign in to Orris to start your own chat.